Literature DB >> 21103864

Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals.

James K Rowlett1, John H Kehne, Ken J Sprenger, George D Maynard.   

Abstract

RATIONALE: Zolpidem is a hypnotic drug that binds to γ-aminobutyric acid type A receptors but lacks consistently demonstrable anxiolytic efficacy.
METHODS: Rhesus monkeys (N = 4) were trained under a multiple schedule in which food-maintained responding was programmed (18-response fixed ratio) for a 5-min period, followed by a 5-min period in which the food-maintained responding was suppressed by response-contingent electric shock (20-response fixed ratio). Doses of zolpidem (range = 0.03 to 1.0 mg/kg, i.v.) were administered 5 min before the session, and responding was re-assessed at three additional 20-min intervals. A similar experiment also was carried out with the non-selective benzodiazepine, triazolam, over a dose range of 0.001 to 0.1 mg/kg, i.v.
RESULTS: Zolpidem did not engender a significant increase in average rates of suppressed responding at earlier time points; however, rates of non-suppressed responding were robustly decreased. At 45- and 65-min post-injection, zolpidem treatment resulted in a dose-dependent increase in rates of suppressed responding. In contrast, the non-selective benzodiazepine triazolam increased rates of suppressed responding in a dose-dependent manner at all four time points, although decreases in non-suppressed responding were less at the later time points.
CONCLUSIONS: These findings suggest that zolpidem has anxiolytic-like effects, but only >25 min after i.v. injection in this rhesus monkey conflict model. It was hypothesized that time-dependent effects on the response rate-suppressing properties of zolpidem become tolerant (i.e., acute tolerance). Because anxiolytic-like effects remain stable throughout the session, the absence of rate-decreasing effects may "unmask" anti-conflict effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21103864      PMCID: PMC3066637          DOI: 10.1007/s00213-010-2093-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

Review 1.  GABA(A) receptor subtypes: dissecting their pharmacological functions.

Authors:  U Rudolph; F Crestani; H Möhler
Journal:  Trends Pharmacol Sci       Date:  2001-04       Impact factor: 14.819

2.  Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA/alpha1-preferring antagonist beta-CCt in squirrel monkeys.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma
Journal:  Psychopharmacology (Berl)       Date:  2002-09-04       Impact factor: 4.530

3.  Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam.

Authors:  D L Margules; L Stein
Journal:  Psychopharmacologia       Date:  1968

4.  Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.

Authors:  C A Paronis; E D Cox; J M Cook; J Bergman
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

5.  Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.

Authors:  R M McKernan; T W Rosahl; D S Reynolds; C Sur; K A Wafford; J R Atack; S Farrar; J Myers; G Cook; P Ferris; L Garrett; L Bristow; G Marshall; A Macaulay; N Brown; O Howell; K W Moore; R W Carling; L J Street; J L Castro; C I Ragan; G R Dawson; P J Whiting
Journal:  Nat Neurosci       Date:  2000-06       Impact factor: 24.884

Review 6.  The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.

Authors:  David J Sanger
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.

Authors:  Joris C Verster; Edmund R Volkerts
Journal:  CNS Drug Rev       Date:  2004

8.  Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects.

Authors:  S L de Haas; R C Schoemaker; J M A van Gerven; P Hoever; A F Cohen; J Dingemanse
Journal:  J Psychopharmacol       Date:  2009-07-31       Impact factor: 4.153

Review 9.  The neurobiology and control of anxious states.

Authors:  Mark J Millan
Journal:  Prog Neurobiol       Date:  2003-06       Impact factor: 11.685

10.  Modelling acute tolerance to the EEG effect of two benzodiazepines.

Authors:  Harald Ihmsen; Sven Albrecht; Werner Hering; Jürgen Schüttler; Helmut Schwilden
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

View more
  3 in total

Review 1.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

2.  Little evidence of a role for the α1GABAA subunit-containing receptor in a rhesus monkey model of alcohol drinking.

Authors:  Eileen K Sawyer; Casey Moran; Madelynn H Sirbu; Melissa Szafir; Michael Van Linn; Ojas Namjoshi; V V N Phani Babu Tiruveedhula; James M Cook; Donna M Platt
Journal:  Alcohol Clin Exp Res       Date:  2013-12-13       Impact factor: 3.455

3.  Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope.

Authors:  Tamara Berdyyeva; Stephani Otte; Leah Aluisio; Yaniv Ziv; Laurie D Burns; Christine Dugovic; Sujin Yun; Kunal K Ghosh; Mark J Schnitzer; Timothy Lovenberg; Pascal Bonaventure
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.